| mRNA |
dabrafenib |
CTRPv2 |
pan-cancer |
AAC |
0.3 |
1e-11 |
| mRNA |
PLX4720 |
CTRPv2 |
pan-cancer |
AAC |
0.2 |
2e-08 |
| mRNA |
IU1 |
CTRPv2 |
pan-cancer |
AAC |
0.21 |
1e-07 |
| mRNA |
salermide:PLX-4032 (12:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.2 |
1e-07 |
| mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
1e-06 |
| mRNA |
etoposide |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
2e-06 |
| mRNA |
tacrolimus |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
4e-06 |
| mRNA |
masitinib |
CTRPv2 |
pan-cancer |
AAC |
0.17 |
6e-06 |
| mRNA |
GDC-0879 |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
1e-05 |
| mRNA |
selumetinib:piperlongumine (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
1e-05 |